Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Duloxetine NDC 59651-280 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 30 mg (30 Capsules Bottle) - duloxetine fig10

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 30 mg (30 Capsules Bottle) - duloxetine fig10

This is a medication description for Duloxetine Delayed-Release Capsules USP which contain 594 mg of et ytrocionds USP, equivalent to 20 mg dulovetine. The medication is distributed by Aurinda Pharma USA and has a unique code TY/DRUGS/19/1093. The usual dosage instructions are provided in accompanying literature, and the medication should be stored in a closed container at the recommended temperature of 20 °C to 25 °C (66 °F to 77 °F). The pharmacist should dispense the medication guide to the patient separately. The text also mentions a manufacturer and a batch number.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 30 mg Blister Carton (10 x 10 Unit-dose) - duloxetine fig11

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 30 mg Blister Carton (10 x 10 Unit-dose) - duloxetine fig11

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 60 mg (30 Capsules Bottle) - duloxetine fig12

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 60 mg (30 Capsules Bottle) - duloxetine fig12

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 60 mg Blister Carton (10 x 10 Unit-dose) - duloxetine fig13

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 60 mg Blister Carton (10 x 10 Unit-dose) - duloxetine fig13

This is a description of a medication called Duloxetine Delayed-Release Capsules. The package contains 100 unit-dose capsules, and each capsule contains 337mg of duloxetine hydrochloride USP equivalent to 30mg of duloxetine. The medication is intended for prescription-only use, and the pharmacist is required to dispense the medication guide provided separately with each patient. The package is child-resistant, and the medication should be kept out of reach of children in a tightly closed container. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), with permitted excursions to 15°C to 30°C (59°F to 86°F). The medicine is distributed by Aurobindo Pharma USA, Inc. and made in India.*

duloxetine fig14

duloxetine fig14

This is a medication guide for Duloxetine Delayed-Release Capsules USP, distributed by Aurobindo Pharma USA, Inc. Each capsule contains 67.3mg of duloxetine hydrochloride USP, equivalent to 60 mg duloxetine. The usual dosage is provided in the accompanying literature. It's important to dispense the medication guide to each patient. The medication should be stored at 20° to 25°C (68° to 77°F) with permitted excursions of 15° to 30°C (59 to 86°F). The drug should be kept in a tightly closed container and out of reach of children. Do not use if seal over the bottle opening is broken or missing. Code: TSDRUGS/9/1993.*

duloxetine fig15

duloxetine fig15

This is a description of a medication called Duloxetine Delayed-Release Capsules. The package contains 100 (10 X 10) unit-dose capsules, and each capsule contains 67.3mg of duloxetine hydrochloride USP, equivalent to 60mg duloxetine. The usual dosage amount can be found in the accompanying literature. The medication guide should be provided separately to each patient when dispensing. The package is child-resistant and should be stored in a tightly closed container at a controlled room temperature between 20°C-25°C (68°F-77°F), with permitted excursions to 15°C-30°C (59°F-86°F). The medication is distributed by Aurobindo Pharma USA, Inc. from their East Windsor location, and it was made in India.*

Figure-2 - duloxetine fig2

Figure-2 - duloxetine fig2

Figure-3 - duloxetine fig3

Figure-3 - duloxetine fig3

Not available.*

Figure-4 - duloxetine fig4

Figure-4 - duloxetine fig4

The text appears to be a graph depicting the percentage of patients who improved with different medication dosages. The medications being compared include Duloxetine at 60 mg twice a day, Duloxetine at 60 mg once a day, and a placebo. The x-axis shows the percent improvement in pain from baseline, while the y-axis represents the percentage of patients who saw an improvement.*

Figure-5 - duloxetine fig5

Figure-5 - duloxetine fig5

The data provided is not sufficient to generate a useful description. It appears to be a table showing the percentage of patients who improved but the specific condition or treatment is not available.*

Figure-6 - duloxetine fig6

Figure-6 - duloxetine fig6

This appears to be a graph showing the percent of patients improved and the percent improvement in pain from baseline for a medication called Duloxetine, which is compared against a placebo. The x-axis shows the percent improvement in pain from baseline (ranging from 0 to 100), while the y-axis shows the percent of patients improved (ranging from 0 to 100). There are also tick marks at 10 increments for both axes. The graph compares the effectiveness of three different doses of Duloxetine (20mg, 60mg, and 120mg once daily) against a placebo.*

Figure-7 - duloxetine fig7

Figure-7 - duloxetine fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg (60 Capsules Bottle) - duloxetine fig8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg (60 Capsules Bottle) - duloxetine fig8

The text appears to be a graph plotting the percentage of patients who improved, with Duloxetine (presumably a medication) and Placebo being compared. The X-axis appears to show a range of values from 0 to 290, possibly indicating the length of the study or the severity of patients' conditions. The Y-axis shows the percentage of patients who improved. However, without further context or a clearer image, it's difficult to determine the exact meaning or significance of the data presented.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg Blister Carton (10 x 10 Unit-dose) - duloxetine fig9

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg Blister Carton (10 x 10 Unit-dose) - duloxetine fig9

This text seems to be a table or a graph with some numerical values related to a medical treatment. It mentions some medication called "Dulowetine" and shows the dosage of 60/120 mg once daily. It also refers to a measure of percentage improvement in pain from baseline with values ranging from 0 to 100. Without further context, it is difficult to understand the purpose of the table/graph or its significance.*

Chemical Structure - duloxetine str

Chemical Structure - duloxetine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.